Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia
Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia
复制标题
CD200 的低表达预示慢性淋巴细胞白血病的治疗时间较短
DOI：
10.18632/oncotarget.6948
复制
发表时间：
2016-03-22
期刊：
影响因子：
--
通讯作者：
Li, Jian-Yong
中科院分区：
文献类型：
--
作者：
Miao, Yi;Fan, Lei;Li, Jian-Yong
CD 200，以前称为OX-2，是一种I型糖蛋白，在多种细胞类型上表达。CD 200在慢性淋巴细胞白血病（CLL）中过度表达。虽然先前的研究已经证实了CD 200在鉴别CLL与其他B细胞慢性淋巴增生性疾病特别是套细胞淋巴瘤中的诊断价值，但CD 200在CLL中是否具有预后意义仍有待确定。我们使用流式细胞术评估了307例连续的、未经治疗的CLL患者的CD 200平均荧光强度（MFI）。使用189.5的CD 200 MFI临界值，这些病例可分为两组。CD 200 MFI较低（< 189.5）的患者的治疗时间（TTT）显著短于CD 200 MFI较高（≥ 189.5）的患者（中位TTT：2个月vs 28个月，p = 0.0008）。然而，CD 200 MFI对总生存期的影响不显著（CD 200 MFI < 189.5：未定义vs CD 200 MFI ≥ 189.5：未定义，P = 0.2379）。在亚组分析中，CD 200 MFI在具有有利特征的患者中保留了其预后价值，例如Binet A期疾病、突变的IGHV状态、正常TP 53或阴性CD 38表达。总之，我们的研究确定了CD 200 MFI作为CLL的潜在预后因子。
CD200, formerly known as OX-2, is a type I glycoprotein that is expressed on a variety of cell types. CD200 has been shown to be overexpressed in chronic lymphocytic leukemia (CLL). Although previous studies have confirmed the diagnostic value of CD200 in differentiating CLL from to other B-cell chronic lymphoproliferative disorders especially mantle cell lymphoma, whether CD200 has prognostic significance in CLL remains to be determined. We evaluated the mean fluorescence intensity (MFI) of CD200 in 307 consecutive, untreated patients with CLL in our center using flow cytometry. Using a CD200 MFI cutoff of 189.5, these cases could be divided into two groups. Patients with lower CD200 MFI (< 189.5) had a significantly shorter time-to-treatment (TTT) than those with higher CD200 MFI (≥ 189.5) (median TTT: 2 months vs 28 months, p = 0.0008). However, the effect of CD200 MFI on overall survival was not significant (CD200 MFI < 189.5: undefined vs CD200 MFI ≥ 189.5: undefined, P = 0.2379). In subgroup analysis, CD200 MFI retained its prognostic value in patients with favourable characteristics such as Binet stage A disease, mutated IGHV status, normal TP53 or negative CD38 expression. In conclusion, our study identified CD200 MFI as a potential prognostic factor in CLL.